Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Drop in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLOGet Free Report) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,600 shares, a decline of 75.4% from the January 15th total of 6,500 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 173,100 shares, the short-interest ratio is presently 0.0 days.

Xilio Therapeutics Stock Performance

NASDAQ XLO traded up $0.04 during trading on Monday, reaching $0.67. The company’s stock had a trading volume of 6,216 shares, compared to its average volume of 280,780. Xilio Therapeutics has a 12 month low of $0.49 and a 12 month high of $3.98. The firm has a 50 day moving average price of $0.69 and a 200 day moving average price of $1.67.

Xilio Therapeutics (NASDAQ:XLOGet Free Report) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.15. Analysts anticipate that Xilio Therapeutics will post -2.76 earnings per share for the current year.

Hedge Funds Weigh In On Xilio Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Xilio Therapeutics by 112.7% in the 3rd quarter. Vanguard Group Inc. now owns 891,533 shares of the company’s stock valued at $2,595,000 after acquiring an additional 472,368 shares during the period. Trustees of Columbia University in the City of New York acquired a new position in Xilio Therapeutics in the 4th quarter valued at approximately $672,000. Bank of America Corp DE acquired a new position in Xilio Therapeutics in the 4th quarter valued at approximately $627,000. Renaissance Technologies LLC acquired a new position in Xilio Therapeutics in the 2nd quarter valued at approximately $220,000. Finally, Millennium Management LLC acquired a new position in Xilio Therapeutics in the 2nd quarter valued at approximately $146,000. 63.49% of the stock is currently owned by institutional investors and hedge funds.

Xilio Therapeutics Company Profile

(Get Free Report)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.

Further Reading

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.